GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2008

Trillium Pockets $12M to Progress Lead Preclinical Candidate

  • Trillium Therapeutics received $12 million from existing investors to advance its lead candidate into clinical development. TTI-1612 is a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

    TTI-1612 is scheduled to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009, Trillium reports.

    Trillium has two other preclinical programs, a CD200-specific anticancer mAb and a CD200Fc fusion protein for autoimmune and inflammatory diseases. The company says that it will use some of the funds to bring these compounds into clinical evaluations as well.

    The participating investors are VenGrowth Private Equity Partners, BDC Capital, and Canadian Medical Discoveries Fund.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?